ClinicalTrials.Veeva

Menu

Effectiveness of Intranasal Versus Intravenous Fentanyl in Preterm and Term Newborns for Pain Prevention

H

HaEmek Medical Center, Israel

Status and phase

Completed
Phase 4

Conditions

Pain

Treatments

Drug: Fentanyl

Study type

Interventional

Funder types

Other

Identifiers

NCT02125201
EMC-0089-13 - CTIL

Details and patient eligibility

About

Neonatal intensive care unit patients undergoes many painful procedures during their hospitalization. Effective pain control in such procedures as intubation, catheterization, central line insertion, chest tube insertion, etc. is an important part of treatment. Opioids administration is a common practice for acute pain prevention. Fentanyl is the preferred opioid due to it rapid onset and short duration of action.

Fentanyl may be given intravenously, transcutaneous transmucosal and intranasal. Intranasal administration is practiced for about 20 years. A rich vascular supply in a nose provides rapid absorption of the drug. This uninvasive root is now popular for pain prevention and treatment. There are about 20 trials with intranasal fentanyl administration to children from 6 month old to 18 years. The investigators did not find information about this way of administration in neonates.

In our pilot study the investigators want to check if intranasal administration of fentanyl is safe and effective in pain prevention in term and preterm neonates during invasive procedures and to compare it with intravenous route of administration.

Enrollment

21 patients

Sex

All

Ages

Under 3 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

Term and preterm neonates that require invasive procedures (elective or semielective intubation, central line insertion , chest drain or abdominal drain)

Exclusion criteria

  1. Neonates with prolonged analgesic treatment before the procedure
  2. Neonates with neurologic problem which can interact with pain assessment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

21 participants in 2 patient groups

intranasal fentanyl
Experimental group
Description:
Intranasal Fentanyl 1.5-2 mcg/kg
Treatment:
Drug: Fentanyl
intravenous fentanyl
Active Comparator group
Description:
Intravenous Fentanyl 1-1.5 mcg/kg
Treatment:
Drug: Fentanyl

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems